Sandhoff disease

Search Trials
Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis
Status:
Completed
Last Changed:
May 19, 2016
First Changed:
Jan 5, 2007
Disease(s):
Gangliosidoses GM2
Intervention(s):
miglustat
A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis
Status:
Withdrawn
Last Changed:
Feb 25, 2013
First Changed:
May 19, 2008
Disease(s):
G(M2) Ganglioside
Intervention(s):
Pyrimethamine
Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses
Status:
Completed
Last Changed:
May 6, 2008
First Changed:
May 6, 2008
Disease(s):
GM2 Gangliosidoses
Intervention(s):
Zavesca (Miglustat)
N-Acetyl-L-Leucine for GM2 Gangliosdisosis (Tay-Sachs and Sandhoff Disease)
Status:
Recruiting
Last Changed:
Sep 6, 2019
First Changed:
Nov 30, 2018
Disease(s):
GM2 Gangliosidosis
Intervention(s):
IB1001
Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease)
Status:
Completed
Last Changed:
Feb 23, 2012
First Changed:
Apr 13, 2010
Disease(s):
Gangliosidoses, GM2
Intervention(s):
PyrimethamineLeucovorin

Connect. Empower. Inspire.